A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheumatica (PMR)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508077-85-00

Acronym

CAIN457C22301E1

Enrollment

182

Registered

2024-06-17

Start date

2024-11-19

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polymyalgia Rheumatica

Brief summary

Incidence of adverse events (AEs) and serious adverse events (SAEs)

Interventions

DRUGSECUKINUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events (AEs) and serious adverse events (SAEs)	—

Countries

Belgium, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026